{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:38:32Z","timestamp":1793943512501,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urolonc.2025.11.005","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T04:49:57Z","timestamp":1765255797000},"page":"119.e7-119.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Jenny Chia-Chen","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Perez-Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedh","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-674X","authenticated-orcid":false,"given":"Jamil","family":"Almohtasib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Korets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria F.","family":"Olumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gershman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.11.005_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0002","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0003","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0004","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0007","doi-asserted-by":"crossref","first-page":"432.e11","DOI":"10.1016\/j.urolonc.2023.06.004","article-title":"Conditional survival following radical cystectomy for urothelial carcinoma of the bladder","volume":"41","author":"Moreno","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5694\/j.1326-5377.2011.tb04171.x","article-title":"When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects","volume":"194","author":"Baade","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0009","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1002\/cncr.28273","article-title":"Dynamic prognostication using conditional survival estimates","volume":"119","author":"Zabor","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0010","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.2009-0211","article-title":"Conditional survival among cancer patients in the United States","volume":"15","author":"Merrill","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0011","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.ejca.2011.11.024","article-title":"Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy","volume":"48","author":"Sun","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0012","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2013.09.050","article-title":"Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urology.2016.07.063","article-title":"Long-term bladder and upper urinary tract follow-up recurrence and progression rates of G1-2 non-muscle-invasive urothelial carcinoma of the bladder","volume":"100","author":"Golabesk","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0014","doi-asserted-by":"crossref","first-page":"238.e19","DOI":"10.1016\/j.urolonc.2018.01.017","article-title":"Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer","volume":"36","author":"von Landenberg","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.15209","article-title":"Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification","volume":"127","author":"Kohada","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0016","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/cncr.33300","article-title":"Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort","volume":"127","author":"Garg","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0017","first-page":"21","article-title":"Conditional survival analyses across cancer sites","volume":"22","author":"Ellison","year":"2011","journal-title":"Health Rep"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0018","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2015.64.7909","article-title":"Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy","volume":"34","author":"Ko","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.prnil.2020.07.004","article-title":"Conditional biochemical recurrence-free survival after radical prostatectomy in patients with high-risk prostate cancer","volume":"8","author":"Park","year":"2020","journal-title":"Prostate Int"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.juro.2016.01.102","article-title":"Dynamic prognostication using conditional recurrence and progression estimates for patients with nonmuscle invasive bladder cancer","volume":"196","author":"Leitner","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0021","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.urology.2009.09.088","article-title":"Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods","volume":"75","author":"Matsumoto","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0022","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00005392-199909010-00019","article-title":"Recurrence and progression in low grade papillary urothelial tumors","volume":"162","author":"Holmang","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0023","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0022-5347(05)68075-5","article-title":"Long-term follow up of initial Ta grade 1 transitional cell carcinoma of the bladder","volume":"162","author":"Leblanc","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0024","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/cncr.22563","article-title":"Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998","volume":"109","author":"Fuller","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0025","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1200\/jco.2006.24.18_suppl.4130","article-title":"Conditional survival in gallbladder carcinoma: results from the SEER 11 dataset","volume":"24","author":"Thomas","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0026","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ygyno.2008.01.033","article-title":"Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001","volume":"109","author":"Choi","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0027","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2003.04.521","article-title":"Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark","volume":"21","author":"Skuladottir","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0028","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.1111\/bju.12115","article-title":"Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time","volume":"111","author":"Bianchi","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0029","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.urology.2011.05.071","article-title":"Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries","volume":"78","author":"Skolarus","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0030","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/sim.1046","article-title":"Prediction of the long-term survival in breast cancer patients according to the present oncological status","volume":"21","author":"Hatteville","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2025.11.005_bib0031","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.10813","article-title":"The long-term clinical course of patients with cutaneous melanoma","volume":"95","author":"Gamel","year":"2002","journal-title":"Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:30:53Z","timestamp":1769257853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1078143925004521"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.11.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}